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With growing interest in the connection between fat and bone, there has been increased
investigation of the relationship with marrow fat in particular. Clinical research has been facil-
itated by the development of non-invasive methods to measure bone marrow fat content
and composition. Studies in different populations using different measurement techniques
have established that higher marrow fat is associated with lower bone density and preva-
lent vertebral fracture. The degree of unsaturation in marrow fat may also affect bone
health. Although other fat depots tend to be strongly correlated, marrow fat has a distinct
pattern, suggesting separate mechanisms of control. Longitudinal studies are limited, but
are crucial to understand the direct and indirect roles of marrow fat as an influence on
skeletal health. With greater appreciation of the links between bone and energy metabo-
lism, there has been growing interest in understanding the relationship between marrow
fat and bone. It is well established that levels of marrow fat are higher in older adults with
osteoporosis, defined by either low bone density or vertebral fracture. However, the rea-
sons for and implications of this association are not clear. This review focuses on clinical
studies of marrow fat and its relationship to bone.
Keywords: bone marrow fat, osteoporosis, bone marrow fat composition, magnetic resonance spectroscopy, bone
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MARROW FAT IN HUMANS
Marrow fat is distinct from white adipose tissue and from brown
adipose tissue (1, 2). The marrow fat depot also appears to be
under separate control from other fat depots. Humans have virtu-
ally no marrow fat at birth, but marrow adiposity increases with
age, particularly during the third decade of life. This well-known
conversion of “red” to “yellow” marrow occurs to varying degrees
at different skeletal sites, with a high percentage in the axial skele-
ton and a lower percentage in the vertebral bodies. For example,
Justesen et al. reported that marrow fat in post-mortem iliac crest
bone biopsies increased from 40% at age 30 to 68% by age 100 years
(3). Both the size and number of adipocytes increase with age (4).
The lifetime pattern of vertebral BMF accumulation appears to
differ in men and women (5, 6). Griffith et al. found that before
age 55 years, BMF is higher in men, but from ages 55–65 years,
women experience a steeper increase in BMF while men have a
gradual increase in BMF with aging (5). As a result, BMF is higher
in women at older ages compared with men.
Higher levels of marrow fat are known to occur in humans
in conditions of starvation (7, 8), alcoholism (9), spinal cord
injury (10), and prolonged bed rest (11), conditions that are also
associated with reduced bone density. Medications that increase
marrow fat include glucocorticoids (12) and thiazolidinediones
(TZDs) (13), highlighting the interconnection of bone formation
and marrow fat accumulation.
The age-related changes in marrow fat and the increases with
specific pathologies have been recognized for years, but progress
in understanding its role and functions has been relatively recent.
In vitro and animal models have provided new insight into the
connection between marrow fat and bone in particular, and these
findings have been extensively reviewed (14–17). Briefly, studies
indicate that marrow fat may function as an indirect marker
of changes in bone and may also play a direct role in bone
health. Changes in the differentiation programs that give rise to
osteoblasts and adipocytes from mesenchymal stem cells in the
marrow can favor adipogenesis over osteoblastogenesis, leading to
increased marrow fat with reduced bone formation. Major control
of mesenchymal stem cell differentiation resides with peroxi-
some proliferator-activated receptor (PPAR)-γ for adipogenesis
and runt-related transcription factor 2 (RUNX2) for osteogene-
sis, with the canonical Wnt/β-catenin pathway playing a central
role. As with other fat depots, marrow fat is an endocrine organ
and may directly influence the survival and function of osteoblasts
and osteoclasts through the release of cytokines, adipokines, and
fatty acids.
NON-INVASIVE MEASUREMENT OF MARROW FAT PROPELS
CLINICAL RESEARCH
Progress in clinical studies of marrow fat and bone has been
greatly facilitated by recent technical advances in our ability to
non-invasively measure marrow fat. Historically, clinical measures
of marrow fat required a biopsy. More recently, non-invasive mea-
surements have become available in the research setting although
these are not generally used clinically. Two techniques using mag-
netic resonance imaging (MRI) are widely used to assess fat in
the bone marrow: magnetic resonance spectroscopy (MRS) and
T1-weighted MRI. Dual energy QCT can also be used to quantify
marrow fat. However, dual energy scans require relatively high lev-
els of radiation. Single energy QCT does not give a reliable measure
of marrow fat.
In MRS measurements, marrow fat is expressed as a percentage
rather than an absolute value. For evaluation of vertebral marrow
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fat, the measurement is acquired on one or more of the lumbar
vertebral bodies (L1–L4). A single voxel is placed in the center
of the vertebral body (Figure 1) (18). The calculation of marrow
fat varies slightly across studies. The percent marrow fat can be
calculated using the large lipid peak at 1.3 ppm (saturated lipids),
ignoring the much smaller lipid peaks at 5.3 (unsaturated lipids)
and 2.0 (residual lipids) (18, 19). Fat content is then calculated
as: fat content= [(I fat/(I fat+ I water)]× 100%. With higher reso-
lution MRI (3 T), fat content has also been reported using three
of these lipid peaks (20). Fat content is then calculated as: fat con-
tent= [(I UL+ I RL+ I SL)/(I UL+ I RL+ I SL+ I water)] × 100%.
Some studies have relied on one vertebral level while others
have reported an average of several levels. The fat content tends to
increase from L1 to L4 (18, 21). Thus, reported marrow fat levels
may vary across studies depending on which levels were included.
In postmenopausal women, vertebral marrow fat levels at separate
vertebral levels from L1 to L4 were highly correlated (18). Although
trabecular spine vBMD is measured at L1 and L2, the correlation
between BMF and trabecular spine vBMD in older women did not
vary substantially when each vertebral level was considered sepa-
rately. The correlations with trabecular spine BMD (L1–L2) were:
−0.23 for BMF measured at L1,−0.20 for L2,−0.23 for L3,−0.28
at L4, and−0.26 for the mean L1–L4 (21).
BMF measured by T1-weighted MRI is also expressed as a per-
centage. Fat fraction is calculated for the whole body and for spe-
cific regions, often the pelvic region, from a whole-body MRI (22).
In contrast to MRS, the T1-weighted MRI is semi-quantitative and
may also have errors due to partial volume effects. However, MRS
is limited to measurement of a small area of the total marrow. Shen
et al. compared measurements of BMF using MRS, T1-weighted
MRI, and a third MR-based method, the Dixon method, and found
good correlations among the different methods (23).
With MRS, it is also possible to quantify the smaller lipid
peaks and assess the degree of saturation of the lipids in mar-
row (Figure 1). Yeung et al. introduced the unsaturation index,
using spectra acquired on a 1.5 T scanner (24). The signal ampli-
tude at about 5.3 ppm (olefinic) was compared to combined
signal amplitudes at 5.3, 2.0, 1.3, and 0.9 ppm, to obtain an
unsaturation index. Degree of lipid unsaturation has also been
assessed using spectra acquired with a 3 T scanner, with a for-
mula that compares signal amplitude at 5.3 ppm to the combined
amplitudes at 5.3 ppm (UL), 2.0 ppm (RL), and 1.3 ppm (SL),
UL (%)= [I UL/(I UL+ I RL+ I SL)] × 100% (20). Resolution of
the smaller peaks is difficult, even at 3 T, and the unsaturation
index should be utilized as a relative index for comparing lipid
composition rather than an absolute measure of marrow lipid
unsaturation.
AN INVERSE RELATIONSHIP BETWEEN MARROW FAT AND
BONE DENSITY
Cross-sectional studies in humans using different methods to
assess bone density and marrow fat have found that lower bone
density is accompanied by higher marrow fat. In 1971, Meu-
nier et al. reported that samples from the iliac crest in women
with osteoporosis had a pronounced accumulation of adipocytes,
relative to age-matched controls (25). Other studies using bone
biopsy to assess marrow fat have also reported a relationship with
osteoporosis (3, 25, 26). Histomorphometry has shown a nega-
tive association between bone marrow fat and bone formation
rates (26).
Studies using non-invasive imaging methods to assess BMF
have also reported an association between higher BMF and lower
BMD (18, 19, 21, 27, 28). Most studies of BMF and bone density
have relied on DXA measurements of bone. Negative associations
between BMF and BMD by DXA have been reported for men (19)
and women (27). Although bone density by DXA is a robust pre-
dictor of fracture risk, the DXA measurements provide only areal
estimates of density, cannot distinguish cortical and trabecular
bone, and are thus limited for purposes of etiologic research. QCT
measurements of bone can potentially provide greater insight into
FIGURE 1 | Measurement of vertebral bone marrow fat using
magnetic resonance spectroscopy. (A) Positioning of box in the middle
of the vertebral body (L3 as example). (B) Example spectrum in vertebral
bone marrow (3T). Four peaks were well resolved: olefinic, double bond
–CH=CH– protons at 5.31 ppm, water protons at 4.65 ppm, the CH2
methylene protons α to a double bond (–CH=CHCH2–), at 2.03 ppm, and
the bulk CH2 methylene protons at 1.3 ppm. Adapted with permission from
Ref. (18).
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the aspects of bone metabolism that are associated with BMF.
In a study of postmenopausal women with and without type 2
diabetes, trabecular spine vBMD and BMF were negatively corre-
lated in both groups (29). In the Iceland AGES–Reykjavik cohort
of older adults, higher BMF was associated with lower trabecular
spine, total hip and femoral neck vBMD, and reduced vertebral
compressive strength, derived from QCT, in women (21). A dif-
ference of about +8% in BMF was associated with differences in
trabecular vBMD of −10.5% (95% CI: −17.2 to −3.2%) at the
spine, −7.08% (−12.51 to −1.31) at femoral neck, and −3.95%
(−7.64 to −0.12%) at total hip. In men, BMF was also negatively
associated with trabecular spine vBMD and with vertebral com-
pressive strength, but associations were not statistically significant.
In men, there was no evident association between BMF and tra-
becular vBMD at the hip. No associations were seen with cortical
vBMD and BMF at either hip site in men or women.
These cross-sectional studies indicate that higher BMF is asso-
ciated with reduced bone density and strength, but longitudi-
nal data on these relationships are limited. Importantly, Griffith
et al. reported that higher BMF at the hip predicts femoral neck
bone loss, measured by DXA, over 4 years in postmenopausal
women (mean age 74 years) (30). Women with BMF above and
below the median experienced average bone loss of 1.6 and 4.7%,
respectively. Changes in BMF were not measured in this study.
DXA and QCT measurements of bone are both vulnerable to
artificially low readings in the presence of higher BMF (31, 32).
Blake et al. estimated that BMF and BMD by DXA are still neg-
atively correlated even after the artificial lowering of BMD with
higher BMF is taken into account (32). It is also reassuring that
studies using biopsy methods rather than imaging to assess bone
and marrow fat have reported negative associations (3, 25, 26).
MARROW FAT AND FRACTURE
Studies have reported a relationship between higher BMF and
prevalent vertebral fracture (3, 21, 33, 34). Justesen et al. reported
higher marrow fat, measured in iliac crest biopsies, in 26 women
with prevalent vertebral fracture compared with age-matched con-
trols (63 vs. 54%, p= 0.02) (3). Wehrli et al. also found higher
marrow fat in those with prevalent vertebral deformities in a study
of older adults (106 women, 33 men) (33). Mean BMF at the spine
was 55 and 45% (p< 0.001) in those with and without a baseline
vertebral fracture, respectively, and remained statistically differ-
ent after adjustment for spine BMD by DXA. In AGES–Reykjavik,
higher vertebral BMF was associated with prevalent vertebral frac-
ture (56.9 vs. 53.7%, p= 0.01), in models adjusted for age, gender,
and trabecular spine vBMD (21). A history of non-vertebral frac-
ture was not associated with BMF in postmenopausal women (20)
or in the Iceland AGES cohort (21). To date, studies of BMF and
incident fracture are not available.
MARROW FAT AND SCLEROSTIN
Sclerostin is a product of osteocytes that is a negative regulator of
bone formation and the target of new therapies for osteoporosis.
Some (35, 36) but not other (37, 38), longitudinal studies have
reported an increased risk of incident fracture with higher scle-
rostin. Somewhat surprisingly, higher circulating sclerostin levels
are associated with higher bone density (35, 37–40). Among older
adults in the Iceland AGES–Reykjavik cohort, serum sclerostin was
positively associated with vertebral bone marrow fat in men, but
not in women (41). These results indicate a possible relationship
between osteocyte activity and bone marrow fat.
POSSIBLE GENDER DIFFERENCES IN THE RELATIONSHIP
BETWEEN MARROW FAT AND BONE
Cross-sectional results from the Iceland AGES–Reykjavik cohort
suggest that the relationships between BMF, bone density, and
bone strength, as well as sclerostin, may differ by gender. Stronger
correlations were observed between BMF and bone in women, but
BMF was associated with prevalent vertebral fracture in men (21).
These gender differences may be due to the effects of sex hormone
levels on BMF and bone. Estrogen as well as testosterone levels
are higher in older men compared with postmenopausal women.
There is evidence from animal and clinical studies that sex hor-
mone levels affect BMF. Rodents experience increased marrow
adiposity with ovariectomy along with decreased bone mass (42),
and conversely estrogen replacement reduces bone marrow adi-
pogenesis in older mice (43). Female rats receiving testosterone
have also been shown to have lower BMF content (44). In post-
menopausal women, treatment with transdermal estrogen reduced
BMF measured in bone biopsies (45). Studies of the relationship
between endogenous estrogen or testosterone levels and BMF in
older adults are not currently available.
MARROW FAT AND CORTICAL POROSITY
Investigation of the relationship between marrow fat and bone
has focused on the amount and composition of fat in the mar-
row cavity. With the growing appreciation of cortical porosity as
a distinct factor in bone health and strength, there is now also
interest in assessing the presence of marrow fat within cortical
pores. New techniques using high-resolution peripheral computed
quantitative tomography (HRpQCT) and 3 T MRS show promise
in distinguishing marrow and blood vessels in pore space (46).
Future studies that can identify the extent of marrow fat in corti-
cal pores may help to identify underlying mechanisms determining
porosity.
LIPID COMPOSITION OF MARROW FAT ALSO ASSOCIATED
WITH BONE DENSITY AND FRACTURE
The composition as well as the quantity of marrow fat may be rele-
vant for skeletal health (47). The relative amounts of saturated and
unsaturated lipids in marrow fat can be measured non-invasively
with MR spectroscopy, allowing exploration of this aspect of mar-
row fat composition. Small studies suggest that a lower proportion
of unsaturated lipids in vertebral marrow fat may be associated
with reduced BMD and greater prevalence of fracture (20, 24).
Yeung et al. assessed vertebral marrow fat content and composi-
tion in 12 premenopausal controls and 50 older women (60+)
without evidence of vertebral fracture (24). The older women
included those with normal (n= 15), low (n= 15), and osteo-
porotic (n= 20) spine BMD. Consistent with other reports, mar-
row fat content was 29% in young control women, and 56, 63,
and 65% in older women with normal, low, and osteoporotic
BMD, respectively. The highest proportion of unsaturated lipids
in marrow fat was found in the younger controls (0.127) and the
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lowest proportion in older women with osteoporotic spine BMD
(0.091). Unsaturation levels in older women with normal and
osteopenic BMD were 0.114 and 0.097, respectively. The unsat-
uration level and marrow fat content were negatively correlated
(r =−0.53, p< 0.0001). In a study of postmenopausal women
(n= 69), Patsch et al. reported an association between history of
fracture and lower unsaturation levels, even after adjustment for
spine vBMD (−1.7%; 95% CI−2.8 to−0.5%) (20).
Marrow fat specimens obtained by iliac crest aspiration dur-
ing hip surgery in 24 postmenopausal women were analyzed with
high-resolution (11.7 T) MR (48). Similar to above studies using
non-invasive measurements, the unsaturation level was lower in
those with low BMD compared to those with normal BMD. How-
ever, in another study using marrow fat specimens obtained during
elective orthopedic surgery, gas chromatography analysis of fatty
acids found similar composition in those with normal, low, and
osteoporotic BMD in all specimens (n= 126), in those from the
tibia (n= 80), and in those from the proximal femur (n= 32) (2).
MARROW FAT, OTHER FAT DEPOTS, AND DIABETES
The role of marrow fat, including the underlying mechanisms of
its relationship to bone, remains poorly understood. One impor-
tant area of clinical investigation has considered the relationship
between marrow fat and other fat depots. The sizes of adipose
depots outside the marrow, including total body, visceral, and sub-
cutaneous depots tend to be strongly correlated with each other
and with body size. In contrast, BMF tends to be independent of
overall body size (3, 22, 49–51) and total body fat (22, 51). How-
ever, a study in the CARDIA cohort (n= 210) found a negative
correlation between BMI and hip BMAT (−0.38; 95% CI−0.53 to
−0.21) (52) and a large study (n= 455) of men and women aged
18–88 years identified a positive correlation between total body fat
and pelvic BMAT (r = 0.24, p< 0.01) (53). In contrast, marrow
fat appears to be consistently elevated in patients with anorexia
nervosa who have very low levels of total body fat (7).
Evidence regarding the relationship between visceral adipose
tissue and marrow fat is inconsistent. Positive correlations between
BMF and visceral adipose tissue (r = 0.34, p= 0.02) have been
reported in obese premenopausal women (50) and in the CARDIA
cohort of middle-aged adults for pelvic BMAT (r = 0.17, p< 0.05)
but not hip BMAT (r = 0.14,p> 0.05) (52). However,other studies
have not found an association (22, 29, 49). In a large cross-sectional
study (n= 455), there was a modest but statistically significant
negative correlation between VAT and pelvic BMAT (r =−0.10,
p< 0.001) (53).
Marrow fat is higher with diabetes in rodent models of type 1
diabetes (54), but there have been few clinical studies of this rela-
tionship and results are inconsistent. In a study of 16 adult men and
women with type 1 diabetes (T1D) and 12 healthy controls, verte-
bral BMF did not differ by diabetes status (55). In postmenopausal
women with (n= 13) and without (n= 13) type 2 diabetes (T2D),
those with T2D had higher BMF (69.3 vs. 67.5%, p= 0.31), but
the difference was not statistically significant (29). However, in
the women with T2D, BMF was positively correlated with A1C
(r = 0.82, p< 0.05). A study in 156 older men reported higher
BMF in those with T2D (59 vs. 55%, p= 0.03) (56). Marrow fat
composition may also differ by diabetes status. Patsch et al. found
that T2D was associated with lower unsaturation levels of vertebral
marrow fat (−1.3%; 95% CI −2.3 to −0.2%) in postmenopausal
women (20).
WEIGHT LOSS, BONE LOSS, AND MARROW FAT
Weight loss in older adults is known to increase bone loss and frac-
ture risk, even among those who are overweight or obese (57, 58).
In states of extreme under-nutrition, BMF is increased while other
fat depots are depleted (7), but little is currently known about
the clinical effects of weight loss on BMF in overweight or obese
adults.
In a short-term (13-week) study of diet-induced weight loss
in 55 women and 17 men, age 19–46 years, participants lost an
average of 9.2 kg (about 9% of body weight) (59). Pelvic BMAT,
measured by whole-body MRI, also decreased by an average of
17.8 cm3 (about 8%). However, total body BMD increased by
0.01 g/cm2 (about 1%); the lack of bone loss in spite of substan-
tial weight loss may be due to the younger age of participants,
use of whole body BMD rather than hip BMD, and/or the short
follow-up time. In a 12-week weight loss study (n= 10), partici-
pants lost 5.2 kg on average, but did not experience a statistically
significant change in pelvic or total BMF, measured by MRI (60).
In a study of the effects of bariatric surgery, changes in verte-
bral BMF were assessed before and 6 months after surgery in 11
morbidly obese women who lost on average 36.5% of total body
fat. Schafer et al. reported little change in vertebral BMF (+0.9%;
95% CI −10.0 to +11.7%, p= 0.84) in women without diabetes
(n= 5) and an apparent decrease in BMF (−7.5%; 95% CI−15.2
to +0.1%, p= 0.05) in those with T2D (n= 6) (61). Bariatric
surgery can dramatically improve insulin sensitivity (62) and the
decrease in BMF in the T2D women may reflect a response to
changes in diabetes status. Women did lose bone after the surgery
at the total hip (4.1%), femoral neck (5.2%), and spine (7.4%).
However, this bone loss, induced by the substantial weight loss of
bariatric surgery, was not accompanied by increases in BMF.
These findings suggest that changes in bone and in marrow
fat are not necessarily linked and that their inter-relationship
is dependent on other factors including diabetes status. Further
investigation of the dynamic relationships among weight loss,
insulin resistance, bone loss, and changes in marrow fat promises
to give us a better understanding of the interplay of marrow fat
and bone.
SUMMARY
Osteoporosis is an important health issue, contributing substan-
tially to morbidity and mortality among older adults. Health care
costs for osteoporosis-related fractures in the United States were
estimated as $19 billion in 2005 and are expected to increase 50%
by 2025 with the growth of the older population (63). Animal
studies have identified BMF as part of the dynamic processes
influencing bone density and strength, and cross-sectional clin-
ical studies have confirmed relationships between higher BMF,
lower bone density, and increased prevalence of vertebral fracture
in older men and women while suggesting gender differences in
the strength of these relationships. This accumulating evidence
points to the potential for BMF to play a diagnostic and ther-
apeutic role in the prevention of osteoporosis (64, 65). At this
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juncture, longitudinal data are needed to determine the relation-
ship between changes in BMF and bone, particularly in the context
of weight loss and changes in other fat depots, and to disentangle
the gender differences observed in cross-sectional studies. A better
understanding of the role of BMF in humans may lead to new
avenues to promote bone formation and thus prevent and treat
osteoporosis.
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